Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine (cas 15191-27-2)

Add time:07/30/2019    Source:sciencedirect.com

SummaryDifferentiating nicotinic acetylcholine receptors (nAChR) to target the high-affinity nicotine α4β2 subtype is a major challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of α4β2, these drugs display full agonism at the α7 nAChR subtype. Site-specific modification of (−)-cytisine via Ir-catalyzed C‒H activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)-modified cytisine ligands retain affinity for α4β2 nAChR and are partial agonists, show enhanced selectivity for α4β2 versus both α3β4 and α7 subtypes, and critically, display negligible activity at α7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized.

We also recommend Trading Suppliers and Manufacturers of Cytisine (cas 15191-27-2). Pls Click Website Link as below: cas 15191-27-2 suppliers

Prev:Novel Cytisine (cas 15191-27-2) derivatives exert anti-liver fibrosis effect via PI3K/Akt/Smad pathway
Next:Agonist and antagonist effects of Cytisine (cas 15191-27-2) in vivo)